Clinical Trials Logo

Clinical Trial Summary

Hypothesis: A validated technique to measure cardiac output (CO) using echocardiography is to calculate stroke volume from the product of LVOT area and LVOT VTI and multiplying the product with heart rate ( CO = SV x H/R; SV = LVOT area x LVOT VTI ).

The LVOT diameter for an individual is more or less a constant measurement. Therefore using the formula mentioned above (SV = LVOT area x LVOT VTI), if the LVOT area is constant, then SV should be proportional to the VTI. This means if a PLR manoeuvre or fluid bolus helps to achieve a rise in SV, then it should be reflected in an increase in VTI as well. If this assumption is true, then an increase in the value of VTI from baseline after fluid challenge (10-15%), should identify a volume responsive patient.


Clinical Trial Description

Can changes in LVOT VTI before and after passive leg raising (PLR) test serve as a sensitive indicator for changes in SV and CO and hence volume responsiveness ?

What is Doppler LVOT VTI? Placing a Pulsed Wave Doppler gate on the LVOT immediately below the opening of the aortic valve while aligning the Doppler beam as parallel to the LVOT/aortic axis as possible with an angle of Doppler alignment <20˚, one may obtain Doppler flow velocity measurements which can help measure the LVOT VTI (Velocity Time Integral). If one integrates this velocity profile between two time points (i.e., calculates the area under the curve), the distance traversed of "a region of blood" flowing during this period may be estimated. Since flow velocity is not constant throughout a flow cycle, all of the flow velocities during the entire ejection period is integrated to measure "distance traversed" of this "region of blood." This integration of flow velocities in a given period of time is called the velocity-time integral (VTI)(1) and yields length or distance (measured in cm).

Goal: Whether VTI (LVOT) measured from the deep transgastric (deep TG) or transgastric long axis (TG LAX ) views reflect changes in stroke volume(SV) and hence cardiac output (CO) measured by the gold standard method (PA CCO by thermodilution) before and after passive leg raising test (PLR).

Hypothesis: A validated technique to measure cardiac output (CO) using echocardiography is to calculate stroke volume from the product of LVOT area and LVOT VTI and multiplying the product with heart rate ( CO = SV x H/R; SV = LVOT area x LVOT VTI ).

The LVOT diameter for an individual is more or less a constant measurement. Therefore using the formula mentioned above (SV = LVOT area x LVOT VTI), if the LVOT area is constant, then SV should be proportional to the VTI. This means if a PLR manoeuvre or fluid bolus helps to achieve a rise in SV, then it should be reflected in an increase in VTI as well. If this assumption is true, then an increase in the value of VTI from baseline after fluid challenge (10-15%), should identify a volume responsive patient.

Why do the investigators wish to do the study? A significant improvement in the field of anesthesiology would occur if we could have a simple yet accurate relatively non-invasive tool to correctly assess fluid responsiveness. Excessive fluid infused in the operating room would prolong mechanical ventilation and stay in the ICU and negatively affect the prognosis of the patient. While monitoring with CCO PA catheter considerable adds to the expense, it has its own complications and as may not be indicated in majority of operative cases. A simple non invasive tool using TEE can significantly add to our understanding of hemodynamics and help guide fluid therapy. If our assumption proves to be correct, then it could be a simple, yet rapid bedside indicator of CO. It could be used as a simple tool to assess fluid responsiveness.

The fundamental reason why a fluid challenge (PLR or fluid boluses) is used is to assess whether there is an increase stroke volume in response to it (2). If the fluid loading fails to improve the stroke volume the fluid challenge/loading serves no useful purpose. In normal physiological conditions both the ventricles operate on the ascending limb of the Frank-Starling curve. Once the left ventricle starts functioning on the 'flat' portion of the Frank-Starling curve, fluid loading has little or no effect on stroke volume. If LVOT VTI could be shown to reflect SV adequately then it will be a relatively simple non invasive dynamic bedside tool to test if fluid boluses are resulting in an increase in VTI hence the SV.

Volume responsiveness has been assessed in literature by measuring the response to fluid boluses or to PLR. Thus a positive test where after a PLR, VTI increased significantly reflecting a positive change in SV and CO, more fluid would be required. Whereas if during PLR, CO and SV diminished reflected by a decrease in the VTI value compared to baseline, the subject would be unlikely to respond to fluid therapy and probably would require inotropic support.

Why PLR ? A recent meta-analysis (3), which pooled the results of eight recent studies, confirmed the excellent value of PLR to predict fluid responsiveness in critically ill patients with a global area under the receiver operating characteristic curve of 0.95.

Limitations of using Doppler VTI: However, use of these equations entails a number of assumptions, including (a) laminar blood flow in the area interrogated, (b) a flat or blunt flow velocity profile such that the flow across the entire CSA interrogated is relatively uniform, and (c) Doppler angle of incidence between the Doppler beam and the main direction of blood flow is less than 20 degrees, so that the underestimation of the flow velocity is less than 6%.

Study population: 50 adult patients undergoing coronary artery bypass surgery. Materials & Methods: After institutional ethics committee approval and personal informed consent, 50 patients undergoing elective coronary artery bypass surgery would be included into the study. Patients with significant arrhythmias, concomitant aortic aneurysms, and esophageal pathology precluding the use of TEE would be considered ineligible for the study.

Patients would be divided into two groups. Patients with normal LV function or mild LV systolic dysfunction (LVEF >40%)(4), assessed by preoperative echocardiography would comprise Group 1, whereas those with preoperative LV moderate to severe systolic dysfunction (LVEF <40%)(4) would be designated to Group 2.

Anesthetic protocol: Patients would be fasted for 8 hours preceding the operation. No i.v. fluids would be administered during this period. Patients would be pre-medicated with their usual cardiovascular medication and 1mg of Lorazepam the night before and would receive 1-2 mg of Midazolam at arrival to the operation theatre. After initiating standard monitoring (ECG, Pulse oximetry, NBP) invasive lines would be introduced under local anesthetic infiltration while the patient would receive supplemental oxygen via facemask. Induction of anesthesia would include 0.05 mg kg_1 Midazolam and 5 mcg kg_1 Fentanyl in addition to Sevoflurane 3-5% titrated to loss of eyelash reflex. Tracheal intubation would be facilitated by Rocuronium 0.1 mg kg_1. Anaesthesia would be maintained by Sevoflurane 1.5-2% titrated to an end tidal value of >1.5%and above supplemented by additional doses of fentanyl up to a total dose of 15-20 mg kg_1. All patients would receive 500 ml of lactated Ringer solution during the induction period.

Hemodynamic and Echocardiographic monitoring. A 7.0Fr triple lumen central line, a 8.5 Fr PA sheath and 7.0 Fr CCO (Continuous Cardiac Output) PA catheter and a 16 G femoral arterial canula would be introduced prior to induction of anesthesia under light sedation and local anesthesia. ````A Philips HD 11XE ultrasound machine (Andover, USA) and transesophageal multiplane echocardiographic probe would be used in all patients. After a comprehensive TEE examination the probe would be positioned to record images from either a deep TG or TGLAX views. Images would be recorded for off-line evaluation. A Board certified echocardiographer proficient in TEE would perform all echocardiographic measurements. Offline echocardiographic measurements would be done by a trained echocardiographer who would be blinded to the study protocol. All hemodynamic measurements will be recorded by a dedicated research nurse.

Experimental protocol: After the induction of anesthesia and initiation of hemodynamic monitoring the patients would be stabilized as necessary and observed for 10-15 min. No further interventions would be allowed during this period, including further fluid administration, changes in anesthetic concentrations or manipulations with inotropic or vasoconstrictor concentrations. A period of at least 5 min of stable BP, heart rate, CVP, and continuous cardiac output would be required before obtaining the baseline set of hemodynamic measurements. A passive leg raising (PLR) maneuver (45%) using protocol described before* in literature would be performed and changes in hemodynamic and echocardiographic parameters would be measured within 1 minute post PLR. The same sequence of PLR and echocardiographic and hemodynamic measurements would be repeated after the end of the operation and before the transfer to the ICU. No measurements would be carried out in the presence of hemodynamic instability or immediately following changes of inotropic or anesthetic medications.

The first set of measurements (HR, MAP, VTI, SV, CO, LVEF and LVOT area ) would be obtained in the semi-recumbent position (45°; designated 'baseline'). Then, the lower limbs would be lifted while straight (45°) with the trunk lowered in the supine position. The second set of measurements of (designated 'during PLR') was obtained during leg elevation, at the moment when VTI plateaued at its highest value. The stroke volume with CCO monitor would be recorded at the moment when it plateaued at its highest value.

NB. Why record changes in VTI/SV etc . within 1 minute post PLR ? Because the maximal hemodynamic effects of PLR occur within the first minute of leg elevation, it is important to assess these effects with a method that is able to track changes in cardiac output or stroke volume on a real-time basis.(5)

NB. Passive leg raising. The passive leg raising test consists in measuring the hemodynamic effects of a leg elevation up to 45°. A simple way to perform the postural maneuver is to transfer the patient from the semirecumbent posture to the passive leg raising position by using the automatic motion of the bed. ;


Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Screening


Related Conditions & MeSH terms


NCT number NCT02292888
Study type Interventional
Source Fortis Hospital, India
Contact
Status Not yet recruiting
Phase Phase 0
Start date December 2014

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A